News

China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...
Endpoints News32m
Keytru­da around head and neck can­cer surgery cuts chance of dis­ease com­ing back
Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...